Universal Ibogaine Announces Results of the Annual Meeting of Shareholders

(TheNewswire)

Calgary, AB – TheNewswire- September 1 4 , 2025 – Universal Ibogaine Inc. ( TSXV:IBO )(“ UI ” or the “ Company ”), a life sciences company with amission to research and deliver medicalized ibogaine-centeredaddiction care, advises of the results of its annual meeting ofshareholders (the “ Meeting ”) which was held in Calgary onSeptember 4, 2025, and of the grant of Restricted Share Units.

Further details of the matters voted on at the Meetingare set out in the Company's Management Information Circulardated July 23, 2025, a copy of which is available on www.sedarplus.ca and was filed onUI’s website.   Specific results for the matters voted on at theMeeting are summarized as follows:

• Election of the Board of Directors (the Board ”) – a totalof nine nominees (as listed below) were elected to the Company’sBoard, with each Board member to hold office until the next annualmeeting of shareholders or until their successors are duly elected orappointed.

• Appointment of Auditors - MNP LLP were re-appointed asthe auditors of the Company for the next fiscal year at a remunerationto be determined by the Board of Directors.

• Employee Equity Incentives Plan (the EICP ”). TheCompany’s 2025 EICP was not re-approved, as it did not meet the 50%minimum shareholder approval.

• Stock Option Plan ( SOP ”) – theCompany’s 2024 SOP was not re-approved, as it did not meet the 50%minimum shareholder approval.  The Company intends to studyinstituting a replacement plan.

Grant of RSUs

UI also advises that, the Board of Directors of theCompany previously approved the granting (subject to regulatoryapproval by the TSX Venture Exchange), effective September 2, 2025, toan Officer of the Company and consultant advisors to the Company, atotal of 13,500,000 Restricted Share Units (“ RSUs ”).  Thesegrant totals include 6,000,000 RSUs Options that were granted to theCompany’s CEO, Nick Karos.  Entitlement to convert the RSUs intocommon shares shall vest one year after the date of grant.

Results of AGM

A total of 129,390,665 (41.4%) of the Company’s312,858,516 outstanding common shares were voted at the Meeting. Specific results for the matters voted on at the Meeting aresummarized as follows:

About UniversalIbogaine Inc.

UI is a life sciences company, with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder(s), andultimately to utilize that treatment protocol globally through plannedfuture licensing agreements. UI is concurrently developing a state of the art holisticaddiction treatment protocol at its Kelburn Recovery Centre (locatednear Winnipeg, Manitoba) that, which when paired with the plannedibogaine detox protocol, is intended to revolutionize the way we treataddiction and drastically improve the lives of individuals andfamilies affected by addiction.

NEITHER THE TSXVENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM ISDEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTSRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.

CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS

?This news release may containforward-looking statements and information. Forward-lookinginformation is frequently characterized by words such ?as"plans", “planned”, "expect","project", "intends", “intended”,"will", "believe", "anticipate","estimate", "scheduled",??"potential", or other similar words, or statementsthat certain events or conditions "may", "should"or ??"could" occur.  The forward-looking statements andinformation are based on certain key expectations ?and assumptionsmade by UI at the date the statements are made.  Although UI believesthat the expectations and assumptions on which theforward-? lookingstatements are based are reasonable, undue reliance should not beplaced on the forward-?looking statements because UI can give noassurance that they will prove to be correct.

Since ?forward-looking statementsaddress future events and conditions, by their very nature theyinvolve ?inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated ?due to a numberof factors and risks, which include, but are not limited to, risksthat required ?regulatory approvals are not obtained. The reader iscautioned that assumptions used in the ?preparation of suchinformation, although considered reasonable by UI at the time of?preparation, may prove to be incorrect and readers are cautionednot to place undue reliance on ?forward-looking information, whichspeaks only to conditions as of the date hereof.  UI does not?undertake any obligation to release publicly any revisions toforward-looking information contained ?herein to reflect events orcircumstances that occur after the date hereof or to reflect theoccurrence ?of unanticipated events, except as may be required underapplicable securities laws. ?

Additional information identifying risks anduncertainties that could affect financial results and the Company iscontained in the Company’s filings with Canadian securitiesregulators, which are available at www.sedarplus.ca

For furtherinformation:

Nick Karos, CEO

Universal Ibogaine Inc.

612-309-3527

Nick.Karos@universalibogaine.com

Related Links

https://universalibogaine.com

Copyright (c) 2025 TheNewswire - All rights reserved.